Optinose Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Common Shares
11 juin 2018 16h25 HE
|
OptiNose, Inc.
YARDLEY, Pa., June 11, 2018 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), announced today the closing of its underwritten public offering of 5,750,000 of its common shares at a price to the...
Optinose Announces Pricing of Public Offering of Common Stock
06 juin 2018 20h21 HE
|
OptiNose, Inc.
YARDLEY, Pa., June 06, 2018 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public...
Optinose Announces Launch of Public Offering of Common Stock
04 juin 2018 16h56 HE
|
OptiNose, Inc.
YARDLEY, Pa., June 04, 2018 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission...
Optinose Reports First Quarter 2018 Financial Results and Recent Operational Highlights
14 mai 2018 07h00 HE
|
OptiNose, Inc.
Optinose confirms retail pharmacy availability of XHANCE commenced in early April Company reports more than 1,300 physicians have prescribed XHANCE through the Xperience program YARDLEY, Pa., May ...
Optinose to Report First Quarter 2018 Financial Results and Corporate Updates on May 14, 2018
07 mai 2018 08h00 HE
|
OptiNose, Inc.
YARDLEY, Pa., May 07, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...
Optinose CEO Peter Miller and President/COO Ramy Mahmoud Named EY Entrepreneur of the Year 2018 Finalists in the Greater Philadelphia Area
23 avr. 2018 16h01 HE
|
OptiNose, Inc.
YARDLEY, Pa., April 23, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Named Emerging Company of the Year by Life Sciences Pennsylvania
15 mars 2018 16h01 HE
|
OptiNose, Inc.
YARDLEY, Pa., March 15, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Highlights
13 mars 2018 07h00 HE
|
OptiNose, Inc.
Optinose expects early April availability of XHANCE in retail pharmacies XHANCE Xperience program launched in early March YARDLEY, Pa., March 13, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a...
Optinose to Report Fourth Quarter and Full Year 2017 Financial Results and Corporate Updates on March 13, 2018
06 mars 2018 16h01 HE
|
OptiNose, Inc.
YARDLEY, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Highlight Data at the 2018 AAAAI/WAO Joint Congress
27 févr. 2018 07h00 HE
|
OptiNose, Inc.
YARDLEY, Pa., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...